Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
复制标题
DOI：
10.1007/s10555-021-09968-0
复制
发表时间：
2021-06
期刊：
影响因子：
--
通讯作者：
Yantasee W
中科院分区：
文献类型：
--
作者：
Nelson MA;Ngamcherdtrakul W;Luoh SW;Yantasee W
在几种乳腺癌亚型中，总肿瘤浸润性淋巴细胞(TIL)水平的升高通常与良好的预后相关。TIL的亚型以各种不同的方式影响肿瘤细胞和免疫细胞，导致亲肿瘤或抗肿瘤的效果。肿瘤浸润性CD8+T细胞和自然杀伤(NK)细胞作为效应细胞对抗肿瘤细胞，与更好的临床预后相关。提高CD8+T细胞和NK细胞的抗肿瘤活性和增殖的免疫治疗方法包括PD-1/PD-L1阻断、CAR T细胞治疗或体外刺激的NK细胞。CD8+T细胞的一个亚群，组织驻留的记忆T细胞，最近也被认为与乳腺癌患者的良好预后有关，并有可能作为预测生物标志物和治疗靶点。肿瘤浸润性B细胞还可以分泌诱导凋亡的抗体，并可作为抗原提呈细胞来激活CD4+和CD8+T细胞。另一方面，调节性T细胞和调节性B细胞通过分泌免疫抑制细胞因子和抑制抗原提呈细胞(APC)的成熟来调节CD8+T细胞和NK细胞的免疫应答。这些调节细胞通常与不良的预后有关，因此抑制它们的调节功能是关键的免疫治疗策略。
Increased levels of total tumor-infiltrating lymphocytes (TILs) are generally associated with good prognosis in several breast cancer subtypes. Subtypes of TILs impact both tumor cells and immune cells in a variety of different ways, leading to either a pro-tumor or anti-tumor effect. Tumor-infiltrating CD8+ T cells and natural killer (NK) cells perform as effector cells against tumor cells and are associated with better clinical outcome. Immunotherapy approaches that improve the antitumor activity and proliferation of CD8+ T and NK cells include PD-1/PD-L1 blockade, CAR T-cell therapy, or ex vivo-stimulated NK cells. A subset of CD8+ T cells, tissue-resident memory T cells, has also recently been associated with good prognosis in breast cancer patients, and has potential to serve as a predictive biomarker and therapeutic target. Tumor-infiltrating B cells also secrete apoptosis-inducing IgG antibodies and can act as antigen-presenting cells to prime CD4+ and CD8+ T cells. On the other hand, regulatory T and regulatory B cells modulate the immune response from CD8+ T cells and NK cells by secreting immunosuppressive cytokines and inhibiting maturation of antigen-presenting cells (APCs). These regulatory cells are typically associated with poor prognosis, therefore rendering suppression of their regulatory function a key immunotherapeutic strategy.
登录
查看更多内容
影响因子：
3.8
作者：
Arias-Pulido H;Cimino-Mathews A;Chaher N;Qualls C;Joste N;Colpaert C;Marotti JD;Foisey M;Prossnitz ER;Emens LA;Fiering S
通讯作者：
Fiering S
影响因子：
45.3
作者：
Adams, Sylvia;Gray, Robert J.;Badve, Sunil S.
通讯作者：
Badve, Sunil S.
影响因子：
4.4
作者：
Almand, B;Clark, JI;Gabrilovich, DI
通讯作者：
Gabrilovich, DI
影响因子：
17.1
作者：
Brentjens RJ;Davila ML;Riviere I;Park J;Wang X;Cowell LG;Bartido S;Stefanski J;Taylor C;Olszewska M;Borquez-Ojeda O;Qu J;Wasielewska T;He Q;Bernal Y;Rijo IV;Hedvat C;Kobos R;Curran K;Steinherz P;Jurcic J;Rosenblat T;Maslak P;Frattini M;Sadelain M
通讯作者：
Sadelain M
影响因子：
24.8
作者：
Ahmadzadeh, Mojgan;Pasetto, Anna;Rosenberg, Steven A.
通讯作者：
Rosenberg, Steven A.